Please assess the completion status of the following clinical trial:

Trial Title: Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~All patients who receive Humira for the treatment of psoriasis vulgaris or psoriatic arthritis not responding to conventional treatment will be evaluated. Eligible patients should be~* those not responding to at least one type of conventional systemic treatment (including ultraviolet therapy) who have skin lesions involving 10% of body surface area or~* patients with intractable eruptions of joint signs/symptoms.~Exclusion Criteria:~Contraindications according to the Package Insert include patients who have any of the following:~* serious infections~* tuberculosis~* a history of hypersensitivity to any ingredient of Humira~* demyelinating disease or a history of demyelinating disease~* congestive cardiac failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Humira (Type: None): Humira 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 80 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).